Walleye Capital
RIGL icon

Walleye Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Walleye Capital’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-37,952
Closed -$1.08M – 5024
2025
Q3 		$1.08M Buy
+37,952
New +$1.14M ﹤0.01% 2035
2025
Q1 		– Sell
-21,621
Closed -$364K – 5002
2024
Q4 		$364K Buy
+21,621
New +$415K ﹤0.01% 3259
2022
Q2 		– Sell
-104,906
Closed -$3.14M – 2677
2022
Q1 		$3.14M Buy
104,906
+31,976
+44% +$866K 0.08% 252
2021
Q4 		$1.93M Buy
+72,930
New +$2.2M 0.06% 336
2020
Q3 		– Sell
-2,900
Closed -$53K – 948
2020
Q2 		$53K Buy
+2,900
New +$52.2K 0.01% 543
2018
Q3 		$488K Buy
+15,192
New +$456K 0.23% 130

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Walleye Capital's RIGL Position: Q4 2025 in Review

Walleye Capital sold out of Rigel Pharmaceuticals (RIGL) in Q4 2025, closing a stake of 37,952 shares — an estimated $1.08M sold.

Walleye Capital first reported a position in RIGL in Q3 2018 and held it in 6 quarters. The position peaked at $3.14M in Q1 2022. 193 funds tracked by Wall St. Rank hold RIGL as of Q4 2025.

  • Walleye Capital reported no remaining Rigel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 37,952 Rigel Pharmaceuticals shares in Q4 2025, an estimated $1.08M.
  • Walleye Capital first reported a position in Rigel Pharmaceuticals in Q3 2018 and held it in 6 quarters.
  • Walleye Capital's Rigel Pharmaceuticals position peaked at $3.14M in Q1 2022.
  • 193 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.